Prognostic biomarkers in lung cancer patients in terms of long-term survival

Authors : Belkis Nihan Coskun, Oğuzhan Sıtkı Dizdar, Şeniz Korkmaz, Engin Ulukaya, Türkkan Evrensel

Pages : 20-22

Doi:10.46310/tjim.875437

View : 26 | Download : 7

Publication Date : 2021-03-07

Article Type : Other

Abstract :Introduction: We aimed to investigate the predictive effect of serum M30 and M65 antigens on long-term prognosis in patients with advanced stage lung cancer before and after the first dose of chemotherapy. Methods: Fourty eight patients with advanced stage lung cancer were included in the study. Demographic data and histopathological characteristics of the patients were recorded. Serum levels of M30 and M65 were studied in 48 patients before chemotherapy, and in 43 patients both before and 48 hours after chemotherapy. Long-term survival was evaluated using Kaplan-Meier curves. The effect of high or low M30, M65 levels and M30/M65 ratio on long-term survival was investigated. Results: The mean age of the patients at the time of diagnosis was 57.52 ± 9.38 years. Fourty six of the 48 patients were men. While M30 value before chemotherapy was 163.23 ± 112.30 U/l; It was measured as 249.74 ± 266.67 U/l 48 hours after chemotherapy (p<0.001). While M65 value before chemotherapy was 415.97 ± 214.63 U/l; It was 656.65 ± 394.15 U/l hours after chemotherapy (p<0.001). Median survival time was calculated as 17 (2-142) months. It was found that the long-term survival of the group with a low M30/M65 ratio before chemotherapy was statistically significantly longer. It was observed that the M30/M65 ratio, or M30 or M65 alone, measured 48 hours after chemotherapy had no predictive value for long-term survival. Conclusion: The M30/M65 ratio before chemotherapy may be a prognostic factor for long-term survival in patients with advanced lung cancer.
Keywords : Lung cancer, M30 and M65 antigen, neoadjuvant therapy, long-term prognosis